Press-release for stocks for NVSEF

symbols : NVSEF

save search

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
Published: 2023-06-12 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.755 0.49% 1.1M

Health Technology

| -2.05% | O: -0.16% H: 0.11% C: -0.76%
KDNY | $40.39 0.22% -0.17% 0

Health Technology

| 68.36% | O: 57.44% H: 0.98% C: 0.55%
novartis therapeutics acquired agreement

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Published: 2022-03-08 (Crawled : 17:00) - voyagertherapeutics.com
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 17.97% | O: -4.98% H: 0.0% C: 0.0%
VYGR | News | $7.51 -1.83% 86K

Health Technology

| 109.02% | O: 31.15% H: 19.58% C: 9.17%
therapeutics report results

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 14.46% | O: -1.03% H: 0.24% C: -0.15%
BGNE | $142.065 2.21% 100K

Health Technology

| -47.05% | O: 8.83% H: 0.11% C: -4.16%
novartis license immunotherapy therapy collaboration

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M

Health Technology

| -34.84% | O: 0.37% H: 0.2% C: -0.79%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 18.27% | O: 6.51% H: 1.75% C: 1.4%
kisqali breast cancer novartis trial

Clostridium Diagnostics Market to grow at a CAGR of 13.69% from 2022 to 2027, Driven by the growing prevalence of CDI - Technavio
Published: 2023-03-27 (Crawled : 11:00) - prnewswire.com
AZNCF | News | $140.3 1.5K

Health Technology

| 2.63% | O: 0.55% H: 1.46% C: -0.08%
TMO | News | $568.365 -1.08% 680K

Health Technology

| 1.29% | O: 0.99% H: 0.78% C: -0.37%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 18.27% | O: 6.51% H: 1.75% C: 1.4%
TRIB | $1.83 530

Health Technology

| 95.72% | O: 1.6% H: 0.0% C: -6.32%
AZN | News | $71.065 0.3% 3.2M

Health Technology

| 4.33% | O: 1.46% H: 0.53% C: -0.25%
growing diagnostics market

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $21.9 2.1% 37K

n/a

| -4.26% | O: 6.23% H: 2.77% C: -10.21%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 2.57% | O: 0.47% H: 0.23% C: -0.99%
pharma business

Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
NVSEF | News | $96.0 52K

Health Technology

| 20.2% | O: 6.92% H: 0.0% C: 0.0%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 22.46% | O: 5.97% H: 0.0% C: 0.0%
novartis growth

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
Published: 2023-03-06 (Crawled : 12:00) - ir.voyagertherapeutics.com
NVSEF | News | $96.0 52K

Health Technology

| 38.3% | O: 2.04% H: 0.0% C: 0.0%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 16.75% | O: 0.34% H: 0.76% C: -0.06%
VYGR | News | $7.51 -1.83% 86K

Health Technology

| 4.65% | O: 5.47% H: 5.45% C: 3.24%
disease license therapeutics payment

Over-The-Counter Drug Market size is set to grow by USD 58.54 billion from 2023-2027, Abbott Laboratories, Achelios Therapeutics Inc. and AstraZeneca Plc, and more to emerge as Some of the Key Vendors, Technavio
Published: 2024-04-22 (Crawled : 22:00) - prnewswire.com
RBGPF | News | $52.06 4.8K

Consumer Non-Durables

| 0.08% | O: 0.98% H: 5.46% C: -0.89%
GLAXF | News | $19.54 2.6K

Health Technology

| -3.74% | O: -3.15% H: 0.0% C: -0.61%
AZNCF | News | $140.3 1.5K

Health Technology

| 1.13% | O: 0.96% H: 2.38% C: 0.17%
NVSEF | News | $96.0 52K

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
RBGLY | News | $10.59 850K

Manufacturing

| 1.7% | O: -0.28% H: 2.18% C: 1.99%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
GSK | News | $40.755 -1.18% 660K

Health Technology

| 1.6% | O: 0.17% H: 1.48% C: 1.43%
ABT | News | $106.78 -0.75% 2M

Health Technology

| 0.49% | O: 0.56% H: 0.41% C: -0.07%
SNY | News | $46.82 -1.82% 510K

Health Technology

| 1.7% | O: 1.7% H: 0.0% C: 0.0%
AZN | News | $71.065 0.3% 3.2M

Health Technology

| 1.03% | O: 0.4% H: 0.0% C: 0.0%
drug astrazeneca set key therapeutics market

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
NVSEF | News | $96.0 52K

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
MOR | News | $18.05 0.06% 79K

Health Technology

| 0.39% | O: 0.39% H: 0.0% C: 0.0%
sales expansion novartis growth

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Published: 2024-04-23 (Crawled : 18:00) - globenewswire.com
NVSEF | News | $96.0 52K

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
lutathera fda first approved tumors for novartis therapy

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
Published: 2023-04-25 (Crawled : 15:00) - biospace.com/
NVSEF | News | $96.0 52K

Health Technology

| 15.2% | O: 5.0% H: 0.0% C: -0.57%
ERAS | $1.89 -2.07% 180K

| -28.52% | O: 0.0% H: 2.59% C: -3.7%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| -1.72% | O: 4.24% H: 0.68% C: -0.77%
melanoma publication potential

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
Published: 2023-05-08 (Crawled : 15:00) - prnewswire.com
NVS | News | $97.755 0.49% 1.1M

Health Technology

| -5.6% | O: -0.11% H: 0.72% C: 0.3%
TCRR 4 | $1.48 3.38% 3.9M

Health Technology

| -21.28% | O: 6.91% H: 1.49% C: -2.49%
INCY | $51.4 -0.48% 380K

Health Technology

| -22.4% | O: 0.03% H: 0.17% C: -1.19%
BNTX | News | $88.15 -0.38% 96K

Health Technology

| -18.39% | O: 4.23% H: 0.0% C: -4.4%
ADAP | $1.08 -5.26% 330K

Health Technology

| -18.57% | O: 1.43% H: 2.11% C: -1.41%
companies report cancer pancreatic global

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
Published: 2022-07-19 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 52K

Health Technology

| 39.1% | O: 3.55% H: 0.0% C: -0.01%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 19.54% | O: 4.22% H: 0.26% C: -0.22%
novartis momentum growth group

Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $19.54 2.6K

Health Technology

| 1.27% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | News | $140.3 1.5K

Health Technology

| 6.9% | O: 3.41% H: 0.0% C: -2.45%
VTRS | News A | $11.37 0.09% 1.2M

Health Technology

| -3.81% | O: -0.08% H: 3.47% C: -0.25%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| -8.25% | O: -2.04% H: 0.19% C: -1.97%
GSK | News | $40.755 -1.18% 660K

Health Technology

| 5.5% | O: 4.04% H: 1.57% C: -3.02%
ABBV | News | $168.51 -0.61% 920K

Health Technology

| 2.8% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $46.82 -1.82% 510K

Health Technology

| -6.39% | O: 1.75% H: 0.0% C: 0.0%
PBYI | $4.87 -5.07% 140K

Health Technology

| 7.66% | O: -0.1% H: 2.31% C: -1.26%
AZN | News | $71.065 0.3% 3.2M

Health Technology

| 5.43% | O: 0.82% H: 0.12% C: -1.64%
AMGN | News | $274.065 0.19% 570K

Health Technology

| -13.06% | O: 0.44% H: 0.2% C: -0.55%
drug breast expected cancer pipeline therapeutics growth market

Topical Corticosteroids Market to Grow by USD 1.08 billion between 2022 to 2027, globally at 4% CAGR - Technavio
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
ALPMF | News | $9.5 1.2K

Health Technology

| -17.75% | O: 4.34% H: 0.0% C: 0.0%
GLAXF | News | $19.54 2.6K

Health Technology

| 1.27% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | News | $140.3 1.5K

Health Technology

| 6.9% | O: 3.41% H: 0.0% C: -2.45%
ALPMY | News | $9.49 480K

Manufacturing

| -17.98% | O: 0.0% H: 1.38% C: 0.26%
VTRS | News A | $11.37 0.09% 1.2M

Health Technology

| -3.81% | O: -0.08% H: 3.47% C: -0.25%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| -8.25% | O: -2.04% H: 0.19% C: -1.97%
GSK | News | $40.755 -1.18% 660K

Health Technology

| 5.5% | O: 4.04% H: 1.57% C: -3.02%
ABBV | News | $168.51 -0.61% 920K

Health Technology

| 2.8% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $46.82 -1.82% 510K

Health Technology

| -6.39% | O: 1.75% H: 0.0% C: 0.0%
AZN | News | $71.065 0.3% 3.2M

Health Technology

| 5.43% | O: 0.82% H: 0.12% C: -1.64%
market

Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight
Published: 2022-06-06 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $96.0 52K

Health Technology

| 28.97% | O: -1.87% H: 2.91% C: 2.91%
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 10.68% | O: 0.31% H: 0.0% C: -1.04%
LLY | News | $731.81 -1.86% 1M

Health Technology

| 143.88% | O: 3.83% H: 0.0% C: 0.0%
OMER | $3.05 -1.29% 120K

Health Technology

| 23.6% | O: 0.8% H: 2.78% C: -13.1%
lupus market

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 13.01% | O: -0.39% H: 0.15% C: -1.07%
INCY | $51.4 -0.48% 380K

Health Technology

| -33.43% | O: 3.73% H: 0.09% C: -3.98%
jakavi treatment disease approval

Global Microarray Market Report 2022: Large-Scale DNA/Gene Chip Initiatives to Drive Sector Moving Forward
Published: 2022-11-09 (Crawled : 21:00) - prnewswire.com
NVS | News | $97.755 0.49% 1.1M

Health Technology

| 19.15% | O: 2.81% H: 0.43% C: -0.2%
MDT | $80.71 -0.71% 1.9M

Health Technology

| 2.52% | O: 3.56% H: 0.11% C: -0.33%
ABBV | News | $168.51 -0.61% 920K

Health Technology

| 14.85% | O: 2.06% H: 0.0% C: -0.62%
ABT | News | $106.78 -0.75% 2M

Health Technology

| 8.17% | O: 3.59% H: 1.37% C: 1.16%
global report chip market

Global Hairy Cell Leukemia Market Analysis & Forecast 2024-2034
Published: 2024-02-02 (Crawled : 03:00) - prnewswire.com
NVS | News | $97.755 0.49% 1.1M

Health Technology